Trial Profile
A Single Rising Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8892
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs MK-8892 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Apr 2013 New trial record